Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma.
Front Immunol
January 2025
Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.
Introduction: Challenges remain in reducing antigen escape and tumor recurrence while CAR-T cell therapy has substantially improved outcomes in the treatment of multiple myeloma. T cell receptor fusion construct (TRuC)-T cells, which utilize intact T cell receptor (TCR)-CD3 complex to eliminate tumor cells in a non-major histocompatibility complex (MHC)-restricted manner, represent a promising strategy. Moreover, interleukin-7 (IL-7) is known to enhance the proliferation and survival of T cells.
View Article and Find Full Text PDFGlobal disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
Blood Cancer J
December 2024
Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM. These disparities are multifaceted and intersect with various factors, including demographics, geography, socioeconomic status, genetics, and access to healthcare.
View Article and Find Full Text PDFSequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström's Macroglobulinemia in Remission: An Unusual Report with Review.
Int J Hematol Oncol Stem Cell Res
October 2024
Apollo CBCC Cancer Care, Ahmedabad, Gujarat, India.
Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon.
View Article and Find Full Text PDFLight-Chain Myeloma Presented as Osseus Tumors: A Case Report.
J Investig Med High Impact Case Rep
December 2024
Brookdale University Hospital Medical Center, Brooklyn, NY, USA.
Article Synopsis
- Light-chain multiple myeloma (LCMM) is a rare type of cancer involving plasma cells, often related to kidney issues and bone damage, but cases presenting as bone tumors are uncommon.
- A 63-year-old male presented with rib pain, and imaging revealed an isolated tumor in his eighth rib along with multiple lytic bone lesions elsewhere, which were confirmed to be caused by plasma cells producing kappa light chains.
- Treatment with daratumumab, bortezomib, lenalidomide, and dexamethasone led to notable improvement, highlighting the diagnostic challenges of LCMM and the need to consider it in bone tumor evaluations.
Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.
J Patient Rep Outcomes
December 2024
Department of Symptom Research, Unit 1450, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Article Synopsis
- - The study aimed to track symptom severity in multiple myeloma (MM) patients during 16 weeks of induction therapy and identify factors that predict high symptom burden, which are often overlooked in clinical settings.
- - Researchers used a symptom inventory to categorize patients into groups with persistently high or low symptom severity, finding that severe symptoms included pain, muscle weakness, and fatigue, affecting patients' quality of life and emotional well-being.
- - Results indicated that 31% of patients experienced high-severity symptoms, with factors like baseline symptom scores and being female linked to worse outcomes, highlighting the need for better monitoring and support during therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!